Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Crouzet Next Grip Generation (2021 GRIP)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: France
Call: New grip generation for active inceptor (H2020-CS2-CFP08-2018-01, 2018)
Start date: 2019-04-01
End date: 2022-07-31
Duration (months): 40.0
Total project cost (EUR): 1225968.75
EU funding (EUR): 500000.0
Participants: 1
Project status: CLOSED

Thanks to our expertise as designer and manufacturer of grips, wheels and electrical function (buttons, trim….) for aircrafts for over 50 years, we want to continue to offer advanced solution for grips. Working with a system integrator like SAFRAN (topic leader) will be a real advantage to efficiently integrate future needs and optimize system integration of our advanced technologies. With 2021 Grip project, Crouzet will define, develop, test and validate technological bricks : low power buttons (switch, analog), visual indicator, hands-on/hands-off and information concentrator to reduce number of wires (space and weight optimization) and exchange information between Grip and calculator of inceptor. These will be integrated in a shipset of grip (left/right) that will be ready for certification. According to evaluation conclusion it could be a fly demonstrator. This project will contribute to maintain and reinforce CROUZET leadership in the domain of grips for aircraft by designing new features and new services. Combined with our industrial facilities loacted in France, we’ll be able to manufacture in volume and consequently widely offer (sale) these innovative solutions to the benefit of system integrators and thus aircraft manufacturers.
Ex vivo gene therapy for GM1-gangliosidosis (GT-GM1)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Italy
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-09-01
End date: 2022-08-31
Duration (months): 24.0
Total project cost (EUR): 171473.28
EU funding (EUR): 171473.28
Participants: 1
Project status: CLOSED

GM-gangliosidosis (OMIM #230500) is a rare, autosomal recessive, neurodegenerative Lysosomal Storage Disorder. It is caused by mutations in the GLB1 gene, encoding the lysosomal hydrolase β-galactosidase. Infantile GM1-gangliosidosis is characterized by neurodevelopmental delay, hypotonia, dysphagia, seizures and death by 3 years of life. Due to the rapid progression and severe nature of this disease, which involves storage of undegraded metabolites and secondary mechanisms of cell damage, correction requires a rapid and robust enzyme delivery to the whole central nervous system (CNS), possibly associated to reduction of local inflammation. Here we propose an ex vivo gene therapy (GT) strategy aimed at preventing or ameliorating the symptoms of the disease in the murine model. Multiple copies of GLB1, alone or in association with a neuroprotective factor, will be delivered ex vivo to hematopoietic stem/progenitor cells by lentiviral gene transfer to determine a sustained and robust expression of the therapeutic enzyme in the CNS of transplanted mice. Genetically modified HSPCs will be administered by a novel approach combining the conventional intravenous route with direct administration into the brain lateral ventricles, to anticipate the myeloid reconstitution in the brain and possibly the therapeutic effect. Our working hypothesis is that this optimized GT strategy could successfully control disease manifestations in the animal model. Moreover, a deep genome-wide genomics analysis will be performed on individual brain cells to elucidate the molecular mechanisms at the basis of the disease and mediating the therapeutic effect. The study will generate a proof of concept for a future clinical development of an efficacious ex vivo GT for infantile GM1-gangliosidosis and will inspire the development of therapies for other LSDs.

Keywords: lysosomal storage disorders,gm1 gangliosidosis
Development of the first Water-based industrial chiller cooled by ambient air (ONDINE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-06-01
End date: 2018-11-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Most industrial production processes require cooling to ensure appropriate temperature for effective operations. Data centers, manufacturing facilities, petrochemical plants, etc. all depend on the degree to which cooling systems provide optimal operating temperatures to tools, workpieces and machinery. These refrigerants often contain fluorinated gases (which pose a threat to the environment), while most natural refrigerants result in usage constraints (compliance with dangerous substances and explosive atmospheres regulations; flammable properties, very high-pressure conditions). Leviathan Dynamics is an innovative startup founded in 2016. LD aims at developing a Water-based industrial chiller cooled by ambient air offering various advantages: abundant and inexpensive base material, no operational risks and 30% higher energy efficiency when compared to current solutions. We have already developed a relevant prototype which has been tested in our laboratory, allowing us to reach TRL 6. Our technology aims at developing vapor-compression mechanical refrigeration systems (chillers) involving closed recirculating systems using a single fluid to produce cold and to transfer cold to the process. We are currently developing the four components of our chillers: heat exchanger blending the circulating loop and the refrigeration loop, high speed compressors, multi-channels condensers and adjustable expansion valves. Starting with two market segments (Laser machine cooling and Electrical cabinets cooling), our ambition is to remove fluorinated gases from the cooling industry. We have already validated our supply chain and we have negotiated distribution agreements (sales under white label, tied sales) with value added resellers. We are applying SME Phase 1 to validate the technical (thermodynamic modelling, aerodynamic optimization, corrosion-resistant materials), business (market study, economic feasibility) and legal (patent applications) feasibility.

Keywords: chiller,water,compressor,expansion valve,heat exchanger,condenser,fluorinated gas,cooling unit
Novel blood-brain barrier permeable CDNF-derived therapeutic peptides for the protection and regeneration of dopamine neurons (THERAPE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Finland
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-09-02
End date: 2022-05-03
Duration (months): 24.0
Total project cost (EUR): 202680.96
EU funding (EUR): 202680.96
Participants: 1
Project status: CLOSED

Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by the progressive loss of midbrain dopamine neurons that leads to the severe movement disorders and several non-motor symptoms. Available PD treatments do not provide long-lasting relief from the symptoms and do not slow down or stop the neurodegeneration. Cerebral dopamine neurotrophic factor (CDNF) was shown to reverse the PD-associated neurodegeneration in vitro and in vivo in animal models. Currently, CDNF is tested in the phase I-II clinical trials in PD patients. Despite of the promising results, CDNF doesn’t pass through the blood brain barrier (BBB) and should be delivered to the brain of PD patients through the risky microsurgery. Thus, there is a great need for the CDNF variants that can penetrate through the BBB avoiding intracranial surgery. In addition, systemic delivery of BBB permeable CDNF would offer a possibility to treat non-motor symptoms. Current proposal combines the cutting-edge molecular neurobiology and nanomedicine to develop the next generation CDNF-derived peptides that will be able to penetrate the BBB. For that 1) the length of CDNF will be reduced to enable penetration through the BBB, 2) CDNF fragment will be mutated to improve its stability in the blood and tissues and 3) CDNF fragment will be conjugated to nanoparticles to increase its stability and ability to penetrate the BBB. Our preliminary data showed the feasibility of this approach and holds great promises for the breakthrough in the treatment of PD. In addition, during the project applicant will be trained into independent group leader through the hands-on training in the top scientific laboratories and by managing the highly innovative research at the interface of different disciplines connecting three excellent scientists: Prof. Saarma, the world leading molecular neurobiology researcher, Prof. Laakkonen, the expert in homing peptides and Prof. Santos, the master of nanomedicine.

Keywords: parkinson s disease,cerebral dopamine neurotrophic factor cdnf,blood brain barrier,neuroregeneration
Genetics, Geography and the Intergenerational Transmission of Maternal Depression Risk (GenGeoRisk)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Norway
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-02-01
End date: 2023-01-31
Duration (months): 24.0
Total project cost (EUR): 214158.72
EU funding (EUR): 214158.72
Participants: 1
Project status: CLOSED

We can all name a family member, close friend, colleague or acquaintance who has suffered from depression. It is a common, pervasive and devastating illness characterised by persistent episodes of low mood. Depression affects individuals across all geographical locations and by the year 2030 it will be the largest contributor to disease burden worldwide. Depression that occurs in women during pregnancy and post-partum is referred to as maternal depression (MD). MD is the leading cause of perinatal mortality and it accounts for ∼20% of all postpartum deaths. Despite this profound individual and societal burden, the aetiology of depression remains poorly understood in part, due to three research barriers: 1) lack of success in identifying genetic variants specific to MD 2) inadequate account of environmental risk factors in genetic research and 3) heterogeneity. GenGeoRisk will address each of these research barriers in the following ways: 1) I will use aggregates of genetic variants (polygenic scores) derived from other successful studies of psychiatric traits to calculate genetic p—a general dimension, which sits at the top of a hierarchical structure of psychopathological dimensions and captures one’s general liability to psychopathology. Genetic p will be used to predict MD symptom risk and resilience in the world’s largest (N= 240 000) pregnancy cohort (MoBa; the Norwegian, mother, father and offspring cohort study) 2) I will use geographical location data from the entire Norwegian population (> 7 000 000) that has been recently linked to MoBa data to illuminate how MD symptoms and genetic p vary across neighbourhoods and diverse Norwegian municipalities 3) I will focus on MD, a less heterogeneous form of major depression, and use genetic p to discover MD subtypes. GenGeoRisk will be the first intergenerational, multi-environmental and DNA based investigation of MD to date.

Keywords: geocode,neighbourhood factors,depression,polygenic scores
Transfer of Multimaterial Flexible Packaging to Circular Economy (FlexPack2Circle)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-12-01
End date: 2023-03-31
Duration (months): 52.0
Total project cost (EUR): 2845520.0
EU funding (EUR): 1991864.0
Participants: 1
Project status: SIGNED

On January 16, 2018 the first-ever European Strategy for Plastics in a Circular Economy has been published. The Commission strives for solutions to get all plastic packaging recyclable by 2030. FlexPack2Circle is a timely action to address the EU directives to stop incineration and landfilling and to recover secondary raw materials. Saperatec is worldwide the first company offering a holistic approach to transfer flexible packaging waste (FlexPack) into the circular economy by a breakthrough technology to recover ALL materials of multimaterial laminates. The patented technology separates PE/aluminum/PET composites in a gentle way without material loss receiving high purity materials. For its innovative approach Saperatec has been awarded with several prizes, such as the Greentech award, Europe’s most renowned environmental and business prize. During FlexPack2Circle the pilot line proven processes will be transferred to industrial scale resulting in a 1st unique recycling plant with a capacity of 18.000 t/a. The business and commercialisation plans are finalized. On short-term Saperatec focuses on the recycling of post-industrial waste from the packaging industry, the market of which is with 400.000 t/a large enough to start the business. More than 200% of the annual yearly plant capacity are already secured by LOIs from potential infeed and outbound customers. The Saperatec business is high risk due to the large capital investments needed. However, currently Saperatec is in the final phase of term sheet preparation with the investors. With the support of the European commission Saperatec is able to accelerate the upscaling and to keep R&D and pilot line activities on high level to further upgrade the material quality, to develop a new packaging design with compatible adhesives and to expand the infeed package portfolio to postconsumer waste. Moreover, FlexPack2Circle is a great chance to extend the Europe- and worldwide contacts to potential customers.

Keywords: recycling,circular economy,flexible packaging
A point of care device to provide real-time blood analysis for chronic diseases. (spinitCompanion)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Portugal
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-12-01
End date: 2017-04-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

biosurfit have developed an In Vitro Diagnostic (IVD) tool - the spinitCompanion - enabling the testing for a wide range of blood parameters that are needed for urgent and accurate diagnosis in order to deliver the correct treatment for chronic diseases. The solution comprises an analyser, a smartphone application and disposable cartridges to process a single drop of blood and provide doctors with real time results. biosurfit's user-friendly device allows for multiple panel blood assays - near or at the patient Point of Care (PoC) - with the use of one single platform. This solution is cheaper and significantly faster than performing such tests recurrently, as chronic conditions require, in a standard lab setting, Furthermore the technology provides a high level of accuracy (comparable to established central lab tests), and quantifies the presence of specific clinical parameters in less than 10 minutes. biosurfit’s solution responds to two main objectives outlined in the EU Health Strategy, which cover both relevant economic and social aspects: 1) Improve the sustainability and efficiency of social and healthcare system 2) Keeping people healthy and active for longer has a positive impact on productivity and competitiveness. The spinitCompanion fully fits with biosurfit’s overall strategy with an innovative product that leverages on the same flagship technology platform - spinit® reader - already on the market and now protected with 20 independent patents. biosurfit’s vision and main goal is to deliver blood analysis testing to the public, removing its reliance on centralised laboratories and long waiting times both for patients and doctors. In this scenario, the SME Instrument project will enable an important step in achieving EU regulation compliance and the development of a full manufacturing and commercialization plan, and strong IP/marketing strategy based on in-depth analysis of European markets.

Keywords: microfluidics,optical imaging detection,haematology,immunoassays,clinical chemistry,blood cell,counts,inflammation,diagnostic,chronic disease,prevention,point of care,patient empowerment
Teaching Race, Belonging, Empire and Migration (TRACTION)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Cultures and cultural production
Panel description: Literary studies, cultural studies, study of the arts, philosophy
Countries involved: United Kingdom
Call: Call for proposals for ERC Proof of Concept Grant (ERC-2020-PoC, 2020)
Start date: 2021-10-01
End date: 2023-09-30
Duration (months): 24.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

Issues of race, belonging, empire, and migration have been at the foreground of public consciousness globally in recent years. Our collective understanding of history and culture is often unsurprisingly at the centre of this discourse, with the foundational role of school education coming particularly under pressure. Imparting a full and complete understanding of issues of race and human mobility is in our collective interest, since the resulting diversity and social inclusion generate a range of socio-economic benefits, from increase in innovation and productivity, to the strengthening of social cohesion and racial equality. The present proposal is to use the research undertaken by the ERC-funded project TIDE (681884) to develop TRACTION, a pioneering platform of training, resources, and community network in one place that will equip teachers to engage with issues of race, belonging, empire, and migration in the classroom. Its dual focus on skills-training and community-building is unique, and designed for both immediate and sustainable impact. It is also designed to be modular and expandable, cuts across subject-boundaries, and can be adapted to different national and international educational systems and examination boards. The ultimate aim will be to translate TIDE’s research into a viable and innovative social enterprise that will that remain available beyond the lifetime of ERC funding, with longstanding and far-reaching socio-economic and cultural impact.

Keywords: race,diversity,migration,education,school education,teaching,history,literature,professional training,digital platform,social networking,social enterprise
Discretization and adaptive approximation of fully nonlinear equations (DAFNE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Mathematics
Panel description: All areas of mathematics, pure and applied, plus mathematical foundations of computer science, mathematical physics and statistics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-07-01
End date: 2026-06-30
Duration (months): 60.0
Total project cost (EUR): 1453937.0
EU funding (EUR): 1453937.0
Participants: 1
Project status: SIGNED

Fully nonlinear partial differential equations (PDE) arise in many applications ranging from physics to economy. They are different from PDEs in mechanics, and the PDE theory relies on the generalized solution concept of so-called viscosity solutions. Monotone finite difference methods (FDM) are provably convergent for approximating viscosity solutions, but are restricted to regular meshes and low-order approximations, thus having limitations in resolving realistic geometries or dealing with local mesh refinement. As viscosity solutions are lacking smoothness properties in general, adaptive approximations are desirable. In contrast to FDM, finite element methods (FEM) offer the possibility of high-order approximations with flexibility in adaptive and automatic mesh design. However, provably convergent FEM formulations for viscosity solutions to nonvariational problems are as yet unknown. With a background in the numerical analysis of PDEs, especially the theory of FEM and adaptive algorithms, DAFNE aims at laying the theoretical and practical foundation for the application of FEM and automatic mesh-refinement algorithms to fully nonlinear equations. The focus is on the large class of Hamilton-Jacobi-Bellman (HJB) equations. They originated from stochastic control problems, but more generally comprise many classical and relevant equations like Pucci's equation or the Monge-Ampère equation with applications in finance, optimal transport, physics, and geometry. The novel approach is to estimate local regularity properties through the control variable in the HJB formulation. This (a) gives rise to new regularization strategies and (b) indicates where the mesh needs to be refined. Both achievements are key to the design of a new FEM formulation. The project is at the frontiers of PDE analysis, numerical analysis, and scientific computing. The long-term goal is to establish the first convergence proofs for adaptive FEM simulations of fully nonlinear phenomena.